Rare Pediatric Disease Voucher Program Gains Temporary Extension From House Committee

US incentive program would gain only four more years, despite calls for a permanent extension.

Capitol House
Pallone did not favor a permanent extension of the rare pediatric priority review voucher program in part because of the strain it puts on the FDA. • Source: Shutterstock

The rare pediatric disease priority review voucher would be saved under pending House legislation, but advocates would have to fight to keep it alive again in 2024.

House Energy and Commerce Committee members on 9 September sent to the full chamber a bill that would continue the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rare Diseases

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.